Hepatitis B Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hepatitis B stocks.

Hepatitis B Stocks Recent News

Date Stock Title
May 9 HOOK HOOKIPA Pharma GAAP EPS of $0.11
May 9 HOOK HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 9 DVAX Dynavax Technologies Corp (DVAX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue ...
May 9 DVAX Dynavax Technologies (DVAX) Q1 2024 Earnings Call Transcript
May 9 BMY Q1 2024 Editas Medicine Inc Earnings Call
May 8 DVAX Dynavax Technologies Corporation (DVAX) Q1 2024 Earnings Call Transcript
May 8 DVAX Dynavax drops 6% as quarterly results miss on both lines
May 8 CODX Co-Diagnostics Q1 2024 Earnings Preview
May 8 DVAX Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
May 8 DVAX Dynavax GAAP EPS of -$0.07 misses by $0.04, revenue of $50.79M misses by $4.19M
May 8 DVAX Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
May 8 ARWR Arrowhead Pharmaceuticals Q2 2024 Earnings Preview
May 8 BMY Bristol-Myers Squibb Insiders Sell US$1.1m Of Stock, Possibly Signalling Caution
May 7 DVAX Dynavax Q1 2024 Earnings Preview
May 7 BMY A Look at Pharma ETFs Post Q1 Earnings
May 7 GOVX GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
May 6 BMY FDA accepts Bristol Myers application for injected Opdivo
May 6 AIM AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
May 6 BMY European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
May 6 BMY U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
Hepatitis B

Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver. It can cause both acute and chronic infections. Many people have no symptoms during the initial infection. Some develop a rapid onset of sickness with vomiting, yellowish skin, tiredness, dark urine and abdominal pain. Often these symptoms last a few weeks and rarely does the initial infection result in death. It may take 30 to 180 days for symptoms to begin. In those who get infected around the time of birth 90% develop chronic hepatitis B while less than 10% of those infected after the age of five do. Most of those with chronic disease have no symptoms; however, cirrhosis and liver cancer may eventually develop. These complications result in the death of 15 to 25% of those with chronic disease.The virus is transmitted by exposure to infectious blood or body fluids. Infection around the time of birth or from contact with other people's blood during childhood is the most frequent method by which hepatitis B is acquired in areas where the disease is common. In areas where the disease is rare, intravenous drug use and sexual intercourse are the most frequent routes of infection. Other risk factors include working in healthcare, blood transfusions, dialysis, living with an infected person, travel in countries where the infection rate is high, and living in an institution. Tattooing and acupuncture led to a significant number of cases in the 1980s; however, this has become less common with improved sterility. The hepatitis B viruses cannot be spread by holding hands, sharing eating utensils, kissing, hugging, coughing, sneezing, or breastfeeding. The infection can be diagnosed 30 to 60 days after exposure. The diagnosis is usually confirmed by testing the blood for parts of the virus and for antibodies against the virus. It is one of five main hepatitis viruses: A, B, C, D, and E.The infection has been preventable by vaccination since 1982. Vaccination is recommended by the World Health Organization in the first day of life if possible. Two or three more doses are required at a later time for full effect. This vaccine works about 95% of the time. About 180 countries gave the vaccine as part of national programs as of 2006. It is also recommended that all blood be tested for hepatitis B before transfusion and condoms be used to prevent infection. During an initial infection, care is based on the symptoms that a person has. In those who develop chronic disease, antiviral medication such as tenofovir or interferon may be useful; however, these drugs are expensive. Liver transplantation is sometimes used for cirrhosis.About a third of the world population has been infected at one point in their lives, including 343 million who have chronic infections. Another 129 million new infections occurred in 2013. Over 750,000 people die of hepatitis B each year. About 300,000 of these are due to liver cancer. The disease is now only common in East Asia and sub-Saharan Africa where between 5 and 10% of adults are chronically infected. Rates in Europe and North America are less than 1%. It was originally known as "serum hepatitis". Research is looking to create foods that contain HBV vaccine. The disease may affect other great apes as well.

Browse All Tags